A Phase 2 interventional study of REGN13335 and Placebo in Pulmonary Arterial Hypertension (PAH), sponsored by Regeneron Pharmaceuticals. Recruiting at 33 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-26.
Sponsored by Regeneron Pharmaceuticals · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 77 studies in Pulmonary Arterial Hypertension with a site in Spain — 13 open to participants now, 18 under way, 7 of them phase 3. Pulmonary Arterial Hypertension · Spain.
Among the 77 studies in Pulmonary Arterial Hypertension with a site in Spain, this one is the 47th largest by planned enrollment of the 73 interventional ones that give a count, is one of 5 that started in 2026, is one of 21 in phase 2, reaches primary completion later than 8 of the 17 other live ones, and was the 74th registered.
701 studies on the registry are indexed under Pulmonary Arterial Hypertension; 141 are open to participants now.
Browse Pulmonary Arterial Hypertension studies →13 of the 77 studies in Pulmonary Arterial Hypertension with a site in Spain are open now. Recruiting first, the newest first:
35Pharma Inc., a GSK company · Sites in Spain, United States, United Kingdom
Ages 18+
Inhibikase Therapeutics · Sites in Spain, United States, Argentina and 11 more countries
Ages 18–75
AllRock Bio, Inc. · Sites in Spain, United States, Australia and 6 more countries
Ages 18–80
Novartis Pharmaceuticals · Sites in Spain, United States, Argentina and 15 more countries
Ages 18–100 · Healthy volunteers
Gossamer Bio USA, Inc. · Sites in Spain, United States, Argentina and 27 more countries
Ages 18–75
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
77 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 27 · Phase 3 39 · Phase 4 5
First in 2003; this study’s year is marked. 5 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 99 is above the median of 40 across 478 interventional studies indexed under Pulmonary Arterial Hypertension.
Median enrollment 162 across the 73 interventional studies, 85 across the 4 observational. Of the 58 that completed or were terminated, 43 (74%) have results posted.
This tab as a report to print or save as PDF → With an account.
72 of 77 have an industry lead sponsor. The 10 most frequent:
Regeneron Pharmaceuticals is the lead sponsor of 413 studies on the registry; 91 are open to participants now.
Of its 126 completed or terminated interventional studies of FDA-regulated products, 80 (63%) have results posted.
Regeneron Pharmaceuticals has 1 study filed under Pulmonary Arterial Hypertension — fewer than ten, so there is no comparison to draw.
5 of the studies in Pulmonary Arterial Hypertension with a site in Spain that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03683186Phase 3United TherapeuticsA Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension | 2026-12 |
| NCT06274801Phase 3Gossamer Bio USA, Inc.Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT) | 2026-12 |
| NCT05649748Phase 3Insmed IncorporatedAn Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Arterial Hypertension (PAH) | 2026-12-31 |
| NCT07175038AllRock Bio, Inc.A Study of ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (ILD-PH) (ROCSTAR STUDY) | 2027-03 |
| NCT06317805AOP Orphan Pharmaceuticals AGInitial Triple Therapy Including Parenteral Treprostinil vs Initial Double Oral Therapy in PAH Group I Patients | 2027-06 |
Add all 5 to your calendar (.ics) → With an account.
Among the 77 studies in Pulmonary Arterial Hypertension with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is researching an experimental drug called REGN13335. The study is focused on participants with Pulmonary Arterial Hypertension (PAH). The aim of the study is to see how safe and effective REGN13335 is in participants with PAH who are taking other PAH medicines.
The study is looking at several other research questions, including:
Key Inclusion Criteria:
Key Exclusion Criteria:
Note: Other protocol-defined Inclusion/ Exclusion criteria apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: REGN13335
Drug: REGN13335
Drug: Placebo
Drug: REGN13335
Drug: REGN13335
Administered per the protocol
Administered per the protocol
Change from baseline in Pulmonary Vascular Resistance (PVR)
Time frame: At week 24
Occurrence of Treatment-Emergent Adverse Events (TEAEs)
Time frame: Through end of study, up to approximately 2.5 years
Severity of TEAEs
Time frame: Through end of study, up to approximately 2.5 years
Change from baseline in circulating N-Terminal pro-B-type Natriuretic Peptide (NT-proBNP) concentrations
Time frame: At week 24
Change from baseline in mean pulmonary artery pressure
Time frame: At week 24
Change from baseline in cardiac output
Time frame: At week 24
Change from baseline in cardiac index
Time frame: At week 24
Change from baseline in right atrial pressure
Time frame: At week 24
Change from baseline in 6-Minute Walk Distance (6MWD)
Time frame: At week 24
Concentrations of functional REGN13335 in plasma
Time frame: Through end of study, up to approximately 2.5 years
Concentrations of total soluble Platelet-Derived Growth Factor-B (PDGF-B) ligands in plasma
Time frame: Through end of study, up to approximately 2.5 years
Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: When Regeneron has: received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry) the legal authority to share the data, and ensured the ability to protect participant privacy
Access criteria: Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf
Data sharing details ↗ · vivli.org
Started May 2026 (actual). Primary completion is estimated for Feb 2028, 21 months after the start.
Of 28 industry-sponsored phase 2 interventional studies under Pulmonary Arterial Hypertension, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 48. This study's planned 21 months is below that.
Counting every sponsor, half of 52 studies reached it within 44 months; a quarter within 26 and three quarters within 65.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pulmonary Arterial Hypertension →